Merck (MRK) Could Be 8% Undervalued Following Strong Phase 3 Cancer Data
Merck (MRK) Could Be 8% Undervalued Following Strong Phase 3 Cancer Data Simply Wall St
Covered in this story
Analyst targets on Merck & Co.
- Freedom Broker: $149 → $140 by Nov 2027 via Investing.com Canada
- Guggenheim: $150 → $171 by Oct 2027 · Buy via Investing.com
- RBC Capital Markets: $145 → $145 by Oct 2027 · Sector Perform via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Merck & Co. →Dalsna Finance is currently tracking 35 stories mentioning Merck & Co., the earliest published 7 Apr 2026.
Summary aggregated from Simply Wall St's public RSS feed. The full reporting belongs to Simply Wall St — please read it on their site.